The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.

Takeshi KawakamiToshiki MasuishiYasuyuki KawamotoHirofumi GoKyoko KatoRyosuke KumanishiKentaro SawadaSatoshi YukiKouji YamamotoYoshito KomatsuKei MuroKunihiro FushikiHiromichi ShirasuKentaro Yamazaki

Published in: Cancer medicine (2022)

The development of chemotherapy including late-line treatments could improve the prognosis of mCRC patients.

Keyphrases

metastatic colorectal cancer
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
squamous cell carcinoma
drug induced
patient reported